Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Study to Evaluate Safety, PK and Biodistribution of an Imaging Agent, 18F-OP-801, After Intravenous Administration to Patients With ALS, Alzheimer's Disease, Multiple Sclerosis, Parkinson's Disease and Healthy Volunteers

NCT05395624 is registered in ClinicalTrials.gov with Ashvattha Therapeutics, Inc. as lead sponsor.

NCT NCT05395624
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05395624 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Study to Evaluate Safety, PK and Biodistribution of an Imaging Agent, 18F-OP-801, After Intravenous Administration to Patients With ALS, Alzheimer's Disease, Multiple Sclerosis, Parkinson's Disease and Healthy Volunteers
Lead sponsor
Ashvattha Therapeutics, Inc.
Phase
Phase 1/2
Overall status
Recruiting
Start date
February 2, 2023
Completion date
May 1, 2026
Enrollment
65 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer disease (ad), amyotrophic lateral sclerosis (als), multiple sclerosis (ms), parkinson disease (pd)